Formulated to Fail Safe: How UK CBD Trade Buyers Should Write Potency Overage Into the Contract

The number on the label is a promise, not a measurement

Any experienced buyer of CBD in the UK knows the arithmetic rarely balances neatly. A bottle declared at 1,000mg seldom contains precisely 1,000mg at the moment of filling, and it almost certainly will not contain that figure twelve months later. The gap between the declared figure and the manufactured figure is what the trade calls overage, and it sits at the heart of a surprising number of disputes that surface months after delivery.

The instinct for most purchasers is to treat overage as a technical footnote — something the formulator handles, something captured in the certificate of analysis, something reassuring. That instinct is costly. Overage is a cost line, a risk allocation, and a contractual lever all at once. Buyers who negotiate hard on price per milligram while leaving the buffer undefined are, in effect, agreeing to fund an unquantified margin with no recourse when the figures drift.

This piece is about putting the buffer on paper. It is written for trade buyers — distributors, retailers buying at volume, private-label operators — and it is deliberately commercial rather than legal. Nothing here constitutes legal advice, and any clause you negotiate should be reviewed by a solicitor familiar with UK supply contracts.

Why the declared potency is always a moving target

Two forces push a finished CBD oil away from its label claim, and they operate in opposite directions.

Laboratory variance. A high-performance liquid chromatography run is not a perfect instrument. Reputable UK labs operating to ISO 17025 will quote an expanded uncertainty on cannabinoid quantification, and the figure is not trivial at low concentrations. Two aliquots drawn from the same batch can legitimately return results that differ by several percentage points. A supplier who formulates to exactly 100% of label is therefore gambling that the release test will land on the right side of the variance — a coin toss repeated across every batch.

Degradation over shelf life. Cannabinoids are not inert. CBD in an oil carrier will drift downward over time, and the rate depends on light exposure, oxygen ingress, temperature and the carrier itself. A product held in a warm stockroom through a British summer will lose potency faster than the same product kept cool and dark. This is why a product that tests at label on day one can be materially under claim at month eighteen.

Overage exists to absorb both effects. Formulating to 110% of claim gives the manufacturer room to release inside specification despite assay variance and to reach the end of the declared shelf life still above the label figure. It is a legitimate engineering decision. What is not legitimate is leaving it undefined and undocumented.

Where overage is honest, and where it becomes slack labelling

The distinction matters, because the two look identical on a certificate.

An honest buffer is specified, tested and disclosed. The release specification states a target potency band — say 105% to 115% of label — and each batch is released only if it falls inside that band. The rationale is documented, the shelf-life data supporting the end-of-life claim is available on request, and the buyer knows precisely what they are purchasing.

Slack labelling is unspecified and opportunistic. A supplier fills to whatever the production run happens to yield, declares the same label figure regardless, and describes the surplus as a quality feature when challenged. There is no band, no end-of-life study, and no way for the buyer to know whether a given pallet is comfortably above claim or marginally below it.

The practical test is straightforward. Ask a supplier for their release specification on a specific SKU. If they can produce a document showing a potency band, a test method, an acceptance criterion and the batch results against it, the overage is engineered. If the answer is a verbal assurance that they "always fill a bit over", it is not.

The three risks an unwritten buffer creates

Cost creep without visibility. Overage is cannabinoid you pay for and largely cannot sell. A 12% buffer on a bulk order is a meaningful sum. If the buffer is not defined, you cannot price it, compare suppliers on a like-for-like basis, or challenge a formulation that quietly drifts upward.

Retail exposure at end of life. When a customer tests a bottle at month fifteen against the label claim, they do not care about release specifications. If the product has fallen below claim, the retailer carries the complaint. Whether they can recover from you depends entirely on what the contract says about the end-of-life figure.

Regulatory and reputational friction. UK enforcement around CBD labelling has tightened considerably in recent years, and a product materially under its declared cannabinoid content is exposed. Overage negotiated properly is a defence; overage left informal is an unmanaged liability.

What to put in the release specification

A workable potency clause has four components. First, a target band expressed as a percentage of label claim, with both a lower and an upper bound. Second, the analytical method and laboratory used for release, named in the contract rather than described generically. Third, an acceptance criterion — the batch passes or it does not, with no discretionary language. Fourth, a retest or stability schedule establishing how potency is tracked through the declared shelf life.

Buyers should also negotiate the treatment of a batch that drifts below the lower bound part-way through shelf life. The options are typically a credit, a replacement, or a sharing of the loss. Silence on this point is, in practice, an agreement that the buyer absorbs it.

Questions worth putting to any supplier

• What potency band do you formulate this SKU to, and can I see the release specification?
• Which laboratory performs release testing, and to what accreditation?
• Do you hold real-time stability data supporting the end-of-life claim, or is it extrapolated?
• What happens contractually if a retained sample tests below claim at month twelve?
• How is overage priced — inside the per-milligram rate, or as a separate line?

The negotiation itself

Overage is rarely a headline term, which is precisely why it is worth raising. A supplier who has never been asked will usually answer candidly, and the answer tells you a great deal about how the rest of their quality system operates. Where a buffer is generous and well documented, there may be room to trade some of it away in exchange for a firmer price or better payment terms — provided the end-of-life claim still holds. Where it is thin and undocumented, the correct response is not to negotiate but to sample and verify.

The broader point is that price per milligram is only half the commercial picture. The other half is what happens to that milligram between the filling line and the customer's hand. A buyer who has written the buffer into the contract knows the answer. A buyer who has not is simply hoping.